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We calculated the health and economic impacts of participation in
a digital behavioral counseling service that is designed to promote
a healthful diet and physical activity for cardiovascular disease
prevention in adults with prediabetes and cardiovascular disease
risk factors (Prevent, Omada Health, San Francisco, California).
This program enhances the Centers for Disease Control and Pre-
vention’s Diabetes Prevention Recognition Program. Participants
completed a 16-week core program followed by an ongoing main-
tenance program.
Methods
Analysis was conducted for 2 populations meeting criteria for life-
style intervention: 1) prediabetes (n = 1,663), and 2) high cardi-
ovascular disease risk (n = 2,152). The Markov-based model simu-
lated clinical and economic outcomes related to obesity and dia-
betes annually over 10 years for the 2 defined populations. Com-
parisons were made between participants and propensity-matched
controls from the community.
Results
The return-on-investment break-even point was 3 years in both
populations. Simulated return on investment for the population
with prediabetes was $9 and $1,565 at years 3 and 5, respectively.
Simulated return on investment for the population with cardiovas-
cular disease risk was $96 and $1,512 at years 3 and 5, respect-
ively. Results suggest that program participation reduces diabetes
incidence by 30% to 33% and stroke by 11% to 16% over 5 years.
Conclusion
Digital Behavioral Counseling provides significant health benefits
to patients with prediabetes and cardiovascular disease and a posit-
ive return on investment.
Introduction
One in 3 adults in the United States has prediabetes (fasting blood
glucose, 100–125 mg/dL); 15% to 30% of those adults will devel-
op type 2 diabetes mellitus within 5 years (1). Diabetes is associ-
ated with an additional $7,900 in average annual medical costs and
with increased risk of cardiovascular disease (2).
The Diabetes Prevention Program (DPP) was a large clinical trial
that showed that lifestyle intervention to improve diet and physic-
al activity reduced type 2 diabetes mellitus onset by 58% over 3
years, with continued clinical benefits observed at 10-year and 15-
year follow-up (3–5). In part because of the DPP results, the US
Preventive Services Task Force (USPSTF) issued recommenda-
tions that overweight or obese adults with at least 1 other risk
factor for cardiovascular disease receive behavioral counseling (6).
Given the success of the DPP, the Centers for Disease Control and
Prevention  (CDC)  Diabetes  Prevention  Recognition  Program
standards were created to track and ensure the quality of lifestyle
intervention programs aimed at diabetes risk reduction, including
guidance for technology-based delivery of lifestyle interventions
(7). Programs like the one we modeled here meet or exceed the
Diabetes Prevention Recognition Program standards by using di-
gital tools such as scales and pedometers connected to systems
through  the  Internet,  curricula  that  are  accessible  online  and
through mobile devices, and online support groups moderated by
health coaches. The contribution of our study is the estimated re-
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turn on investment for adults voluntarily participating in a digital
behavioral counseling program, calculated by simulating clinical
and economic outcomes for patients with prediabetes and addi-
tional cardiovascular disease risk factors.
Methods
We used a previously published microsimulation model of the
economic and clinical benefits of disease prevention (8–10) to cal-
culate return on investment associated with participation in a digit-
al behavioral counseling program (with 2 components, Prevent
and Sustain, Omada Health, San Francisco, California). We ap-
plied 26-week weight loss results to simulate potential health and
economic outcomes over the subsequent 10 years on 2 popula-
tions defined by prediabetes status and presence of other cardi-
ovascular disease risk factors.
Published results from a pilot study of Prevent analyzed 187 parti-
cipants who started the program and met eligibility criteria, includ-
ing a previous diagnosis of prediabetes (11). Average weight of
participants declined 5.0% at 16 weeks and 4.8% at 12 months,
which was accompanied by an average 0.4% decrease in hemo-
globin A1c (HbA1c). The 144 participants who continued into the
Sustain phase experienced an average weight loss of 5.4% at week
16 and 5.2% at 12 months, as well as a 0.4% reduction in HbA1c
after 12 months (11).
To calculate return on investment, the average program cost for an
active participant was estimated at $1,300 over 3 years, including
an up-front cost of $400 for weight loss courses and $900 for the
Sustain program over the following 3 years ($400 at the end of
year 1, $300 at the end of year 2, and $200 at the end of year 3).
Model population
The study sample consisted of 2,371 people enrolled in Prevent
between 2012 and 2014 and in the program for at least 16 weeks,
older than 18 years, and with baseline body mass index (BMI) of
24 kg/m2 or higher. We calculated the difference of each parti-
cipant’s beginning body weight and last available weight recorded
between week 17 and 26.
Prevent collects BMI and demographic data on participants but
does not collect additional clinical and health risk information re-
quired by the computer model to simulate disease onset and med-
ical expenditures or to determine whether participants have predia-
betes or cardiovascular disease risk factors. Required information
for modeling includes HbA1c, systolic blood pressure (SBP) and
diastolic blood pressure (DBP), total cholesterol and high-density
lipoprotein cholesterol (HDL-C), current smoking status, and pres-
ence of chronic medical conditions (eg, treated or untreated hyper-
tension, diabetes, cardiovascular disease, and history of myocardi-
al infarction or stroke). To extrapolate these missing variables, we
performed a 1:1 propensity score match (on age, sex, race/ethni-
city, and starting BMI) with the 2011–2012 National Health and
Nutrition Examination Survey (NHANES) population.
Diabetes Prevention Recognition Program enrollment criteria in-
clude adults with a BMI of 24 kg/m2 or higher and at least 50% of
program participants have diagnosed prediabetes or history of dia-
gnosed gestational diabetes (7). USPSTF recommends behavioral
counseling for overweight or obese adults with 1 or more addition-
al  risk  factors  for  cardiovascular  disease  (6).  On  the  basis  of
propensity matching with NHANES, the demographics and BMI
of Prevent participants suggested that if a random sample of over-
weight and obese adults participated, then approximately 53%
would have prediabetes and 77% would meet the USPSTF criteria
of having at least 1 risk factor for cardiovascular disease.
Population with prediabetes. Using propensity scoring, we
matched 1,663 Prevent participants to a person in NHANES
with prediabetes (HbA1c 5.7%–6.4%) and the same demo-
graphics and BMI.
1.
Cardiovascular disease risk population. We matched 2,152 Pre-
vent participants to adults in NHANES with the same demo-
graphics and BMI and who had at least 1 cardiovascular dis-
ease risk factor.
2.
Overweight and obese population. We matched all 2,371 Pre-
vent participants to an NHANES person with the same demo-
graphics and BMI.
3.
Prevent participants not matched through propensity scoring were
predominantly young women with high BMI for whom there were
few similar adults in NHANES.
The starting (time 0) characteristics of these analytic cohorts are
summarized in Table 1. These participants constitute the intent-to-
treat cohorts. We also analyzed starters (participants completing
≥4 lessons) and completers (completing ≥9 lessons) according to
CDC guidelines (7).
Simulation modeling
We used a Markov-based microsimulation model in which a per-
son’s characteristics are used to predict health outcomes in the up-
coming year.  Detailed documentation of  the model  prediction
equations for disease onset and mortality, data and assumptions
that underlie the model, calculations for quality-adjusted life years
(QALYs), and validation results are published elsewhere (8,9).
The simulation model uses an annual cycle, with weight loss oc-
curring at time 0, after which body weight follows a natural his-
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tory of weight change (increasing or decreasing) as a person ages
(8,9). Change in body weight affects HbA1c, blood pressure, and
cholesterol  levels,  and these clinical  outcomes combined with
demographics, smoking status, and presence of chronic conditions
in turn are used in prediction equations for disease onset, severity,
and mortality. Equations predicting annual disease states are based
on published clinical and observational studies (8,9). Simulated
annual medical expenditures, estimated with the 2008–2012 Med-
ical Expenditure Panel Survey by using a generalized linear mod-
el with gamma distribution and log link,  reflect  patient demo-
graphics; presence of diabetes, hypertension, congestive heart fail-
ure, ischemic heart disease, retinopathy, and end-stage renal dis-
ease; history of myocardial infarction, stroke, and various cancers;
smoking status; and body weight. Regressions results are pub-
lished elsewhere (9).
To fully account for real-life uncertainty in the effectiveness of
weight loss programs, each person’s actual 26-week weight loss
was used in the simulation. All medical costs were converted to
2014 dollars by using the medical component of the consumer
price index (12). Dollar estimates are in 2014 US dollars (using
3% discount rate) unless otherwise indicated.
Construction and validation of the model followed recommenda-
tions from the International Society for Pharmacoeconomics and
Outcomes Research for best practices and transparency (13,14).
Validation activities included review by experts in obesity, endo-
crinology, modeling, and health economics; internal and external
quantitative validation (8,9); and sensitivity analysis to test the ro-
bustness of model conclusions under additional uncertainties. As
part of the sensitivity analysis, we simulated outcomes if each per-
son’s weight loss varied by ±1 percentage point (absolute change)
relative to actual observed weight loss. For example, a person who
experienced 4.5% weight loss was also modeled with 3.5% and
5.5% weight loss. Because the average weight loss of Prevent par-
ticipants was about 5%, a ±1 percentage-point sensitivity analysis
is equivalent to ±20% (relative change) around baseline weight
loss and simulates the implications if average weight loss were ap-




The constructed population with prediabetes was on average aged
49.8 years (standard error [SE], 0.30 y), and 30.8% were men (Ta-
ble 1). The average starting BMI was 33.9 kg/m2 (SE, 0.15 kg/m2),
and HbA1c was 5.9% (SE, 0.01%). Starter and completer sub-
groups were similar to the overall intent-to-treat cohort.
On  average,  participants  with  prediabetes  lost  5.1%  of  body
weight. The simulated reduction in diabetes onset was 28%, 30%,
and 26% over 3, 5, and 10 years, respectively (Table 2). Parti-
cipants with a history of cardiovascular disease–related events
showed a modest 9% to 17% decrease for additional cardiovascu-
lar disease events, and simulated incidence of stroke declined 16%
over 5 years. Simulation results suggest reduced cumulative med-
ical expenditures over 3, 5, and 10 years by, $1,310, $2,865, and
$9,217, respectively.
Average weight loss (recorded on or before week 26) among pro-
gram completers  (6.0%) exceeded average weight  loss  among
starters (5.3%) and the intent-to-treat cohort (5.1%). Both groups
had simulated positive return on investment within 3 years. Simu-
lated cumulative medical savings over 3, 5, and 10 years averaged
$1,533,  $3,317,  and $10,043 for  program starters  and $1,730,
$3,893, and $12,026 for program completers.
Population at risk for cardiovascular disease
The population meeting USPSTF screening criteria was on aver-
age aged 49.0 years (SE, 0.27 y), 24.1% were male, and average
starting BMI was 34.4 kg/m2 (SE, 0.14 kg/m2) (Table 1). An es-
timated 62.6% had prediabetes, 17.1% had diabetes, and 20.3%
had normal blood glucose levels.
Weight loss among this analytic cohort averaged 5.0%. Simulated
average  reductions  in  cumulative  medical  expenditures  were
$1,396, $2,812, and $7,951 over 3, 5, and 10 years, respectively
(Table 3). The average weight loss among starters and completers
was 5.3% and 6.0%, respectively. Simulated medical savings over
3, 5, and 10 years were higher for program completers versus pro-
gram starters.
Return-on-investment analysis
In the intent-to-treat cohort, the projected break-even point was 3
years for both the population with prediabetes and the population
with cardiovascular disease risk factors (Figure 1). At 3, 5, and 10
years, estimated return on investment averaged $9, $1,565, and
$7,918 for the population with prediabetes and $96, $1,512, and
$6,651 for the population at risk for cardiovascular disease. The
percentage of return on investment in each year can be calculated
by dividing “total return at or before current year” by “total invest-
ment at or before current year.” According to this algorithm, 39%,
64%, and 101% of program investment on the population with
prediabetes was recouped at year 1, 2, and 3, respectively. For the
population with risk factors for cardiovascular disease, 48%, 75%,
and 107% of the investment was recouped at year 1, 2, and 3, re-
spectively.
PREVENTING CHRONIC DISEASE VOLUME 13, E13
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY     JANUARY 2016
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
www.cdc.gov/pcd/issues/2016/15_0357.htm • Centers for Disease Control and Prevention       3
Figure 1. Projected average return on investment on weight loss program
participation, Prevent digital behavioral counseling program, 2012–2014.
Return on investment was calculated as the difference between the medical
cost savings due to improvements in health and the cost of participating in
the program (Return on investment = direct medical saving – Prevent initial
program cost at year 0 – Prevent maintenance costs). Abbreviation: USPSTF,
US Preventive Services Task Force.
 
Discussion
Previous work found that Prevent is effective in reducing body
weight and improving HbA1c levels among a population with pre-
diabetes (11,15). Using microsimulation, we modeled the clinical
and economic implications one would expect with this level of
weight loss given the characteristics of program participants and
whether participants had prediabetes or were at risk for develop-
ing cardiovascular disease.
Given the central role of weight loss in the model, we conducted
sensitivity analysis around weight loss to test its influence on pro-
gram benefits. Findings were similar for the populations at risk for
prediabetes and cardiovascular disease (Figure 2). In the popula-
tion with prediabetes, simulated medical saving varied from −22%
to 19%, and diabetes onset varied from −7% to 7%. Sensitivity
analysis results on the population at risk for cardiovascular dis-
ease are in the Appendix.
Figure  2.  Tornado  diagram  for  the  sensitivity  analysis  on  weight  loss
percentage over 10 years in a population with prediabetes, Prevent digital
behavioral  counseling  program,  2012–2014.  Default  weight  loss  for  the
population  with  prediabetes  is  5.13%;  diabetes  onset  is  based  on  the
absolute number of new diabetes cases in the time period.
 
Study findings suggest that the 2014 US dollars value of reduced
medical expenditures from achieving the average cumulative res-
ults of Prevent over 3, 5, and 10 years is, respectively, $1,310,
$2,865, and $9,217. Among a broader population meeting USP-
STF criteria, the savings are $1,396, $2,812, and $7,951 over 3, 5,
and 10 years, respectively. Our findings agree with a CDC-initi-
ated study, which concluded that implementing the USPSTF beha-
vioral  counseling recommendations can be cost  effective (16).
Certain subgroups in the general obese populations, such as the
middle-aged population with class III obesity (BMI ≥40 kg/m2)
and hypertension, could enjoy even higher savings in direct med-
ical expenditures. Subgroup analysis in obese populations is a top-
ic for future research.
Our findings are similar to previously published cost and disease
estimates associated with implementing a lifestyle intervention in
people with prediabetes — that achieving the average weight loss
and HbA1c outcomes of the DPP trial could reduce cumulative
medical expenditures by $10,600 over 10 years (2014 dollars, us-
ing a 3% discount rate), on average (8). A comparison of the out-
comes from our microsimulation and those from the DPP and DPP
Outcomes Study (DPPOS) has been detailed (8,9). One challenge
of this comparison was that DPPOS was based on an obese popu-
lation with many risk factors and a very high risk of developing
type 2 diabetes. A second challenge was that after completion of
the DPP study (at 3 years) all participants were offered the life-
PREVENTING CHRONIC DISEASE VOLUME 13, E13
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY     JANUARY 2016
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
4       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2016/15_0357.htm
style intervention, thus diluting the potential long-term benefits in
the DPPOS. However, our simulation results align with those of
the study in the following ways. In the first 3 years, the benefits of
lifestyle intervention were smaller in our simulation, which can be
explained by a lower-risk population. Over 10 years, the benefits
became larger — consistent with no cross-contamination of the in-
tervention and control groups as occurred when the DPP control
group later began the lifestyle intervention. One exception is re-
duction in  diabetes  onset  after  lifestyle  intervention,  which is
lower in the simulation than in the DPP or DPPOS at both year 3
(28% vs 58%) and year 10 (26% vs 34%) (3,4).
We collected weight loss data for 26 weeks, and the return-on-in-
vestment analysis assumes that participants retain this weight loss
with natural weight changes one would expect associated with
aging (with average annual weight gain through approximately
age 60). Findings from early Prevent participants found that after 2
years, a large proportion of the population has maintained their
weight loss (15). Specifically, program completers lost an average
4.9% after 1 year and 4.3% after 2 years. The DPPOS found that
in  the  5  years  following  DPP lifestyle  intervention  there  was
gradual weight gain, with participants sustaining approximately
one-third of their original weight loss between years 5 and 10 (4).
Prevent has an integrated 3-year Sustain component aiming at
maintaining initial  weight loss for an extended period of time.
Nevertheless, we tested a scenario in which participants regain
weight after year 1 at the same speed observed in DPPOS. Under
this  scenario,  we  found  the  return-on-investment  break-even
timeline increased by about 4 months and 10-year total savings
dropped from $7,918 to $5,591 for the population with predia-
betes.
Clinical trials and community-based programs have shown that
lifestyle intervention can be effective in reducing body weight and
improving health outcomes. An estimated 86 million adults have
prediabetes, and many of these adults are candidates for lifestyle
intervention (1). The population covered by the USPSTF recom-
mendations for preventing cardiovascular disease is likely even
larger.  Treating  a  population  this  size  requires  alternative
strategies to those tested in the in-person DPP. This study sug-
gests that online programs may offer a scalable,  cost-effective
solution. Using Internet-based technologies can both help over-
come geographic and scheduling barriers and allow participants to
review material at their own pace.
Using a previously published and validated microsimulation mod-
el, we simulated how the clinical outcomes achieved by Prevent
participants translate into reduced future prevalence of disease and
reduced medical expenditures. Model strengths and limitations are
discussed elsewhere in detail (8,9). Strengths include the ability to
simulate outcomes over an extended period, using disease predic-
tion equations based on published epidemiologic studies and ac-
counting for the characteristics and outcomes of program parti-
cipants. Limitations include the use of data from multiple sources
(both US and non-US), older data such as those from the Framing-
ham study when newer data were unavailable, and some disease
onset predication equations based on a general population rather
than a population with prediabetes or risk factors for cardiovascu-
lar disease. Additional limitations specific to this study include
Prevent participants chose to participate in the intervention.
This means that results can be generalized to other populations
of voluntary participants but not necessarily to the general pop-
ulation.
1.
Weight loss data were the only clinical data collected on Pre-
vent participants, so we used propensity matching (using age,
sex, race/ethnicity, and BMI) with NHANES data to create the
analytic files that contained all the starting values for clinical
inputs needed to run the simulation. We could not directly ob-
serve if Prevent participants had prediabetes or risk factors for
cardiovascular disease.
2.
We were unable to find a match for 708 Prevent participants in
the NHANES data. Unmatched people were overwhelmingly
young women with much higher BMI than observed in
NHANES participants. Unreported findings suggest that ex-
tremely obese people have higher return on investment from
weight loss relative to less obese people, but younger people
have lower short-term return on investment relative to older
people.
3.
DPP-based programs offered online can increase access to a cost-
effective lifestyle intervention to millions of adults with predia-
betes or who are at high risk for cardiovascular disease. In addi-
tion  to  improving  health  outcomes,  such  an  intervention  can
provide a positive return on investment for payers.
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Tables
Table 1. Characteristics of Population With Prediabetes and Population at Risk for Cardiovascular Disease at Baseline, Prevent Di-
gital Behavioral Counseling Program, 2012–2014a
Patient
Characteristic
Population With Prediabetes US Preventive Services Task Force Population









Age, mean (SE), y 49.8 (0.30) 50.6 (0.31) 51.7 (0.33) 49.0 (0.27) 50.9 (0.27) 50.9 (0.29)
BMI, mean (SE), kg/
m2
33.9 (0.15) 33.9 (0.16) 33.7 (0.17) 34.4 (0.14) 34.0 (0.14) 34.0 (0.16)
SBP, mean (SE),
mm Hg
126.8 (0.43) 126.7 (0.46) 126.5 (0.50) 126.3 (0.41) 126.4 (0.41) 126.4 (0.45)
HDL-C, mean (SE),
mg/dL
49.8 (0.34) 49.8 (0.36) 49.6 (0.39) 50.3 (0.34) 50.5 (0.34) 50.5 (0.38)
T-C, mean (SE), mg/
dL
201.3 (0.97) 200.9 (1.02) 200.3 (1.12) 203.0 (1.00) 203.0 (1.00) 203.0 (1.09)
Hemoglobin A1c,
mean (SE), %
5.9 (0.01) 5.9 (0.01) 5.9 (0.01) 6.0 (0.02) 6.0 (0.02) 6.0 (0.03)
Male, % 30.8 30.1 31.7 24.1 24.8 24.8
Prediabetes, % 100 100 100 62.6 62.8 62.8
Diabetes, % 0 0 0 17.1 16.8 16.8
Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; SE, standard error; T-C, total cholesterol.
a All values estimated from a population with individuals matched from the National Health and Nutrition Examination Survey.
b Participants completing ≥4 lessons.
c Participants completing ≥9 lessons.
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3-year 5-year 10-year 3-year 5-year 10-year 3-year 5-year 10-year
Disease onset relative reduction, %
Diabetes 27.9 29.5 26.0 31.4 32.4 28.0 33.3 36.1 31.2
History of ischemic heart disease 9.1 12.7 14.2 9.9 11.9 12.3 16.6 15.1 14.5
History of myocardial infarction 11.9 10.9 16.3 5.9 10.5 15.9 16.2 17.2 20.1
History of congestive heart failure 14.6 15.0 15.4 13.1 14.9 14.7 15.3 16.6 17.6
History of stroke 15.2 16.3 15.7 15.1 16.1 15.5 21.3 21.8 18.7
Obstructive sleep apnea 9.6 10.0 9.8 11.2 10.7 10.3 11.7 12.1 11.4
Major depression episodes 9.0 10.0 10.9 11.0 11.5 12.4 12.0 13.6 14.4
Medical expenditures saving, $ per capitac 1,310 2,865 9,217 1,533 3,317 10,043 1,790 3,893 12,026
QALYs increase per person 0.05 0.10 0.23 0.06 0.11 0.26 0.06 0.12 0.28
Sick days reduction per person 0.4 0.7 1.6 0.4 0.8 2.0 0.5 0.8 1.8
Average 3-year program costs, $c 1,300
Average weight loss, % 5.1 5.3 6.0
Sample size, n 1,663 1,462 1,232
Abbreviation: QALYs, quality-adjusted life years.
a Participants completing ≥4 lessons.
b Participants completing ≥9 lessons.
c Dollar estimates are 2014 US dollars value using a 3% discount rate.
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3-year 5-year 10-year 3-year 5-year 10-year 3-year 5-year 10-year
Disease onset relative reduction, %
Diabetes 30.1 32.8 30.4 32.8 35.1 32.3 35.0 38.0 35.9
History of ischemic heart disease 10.6 9.3 9.2 10.4 11.1 13.0 11.9 13.1 13.1
History of myocardial infarction 11.8 9.0 14.0 8.2 10.6 13.7 11.3 12.2 16.7
History of congestive heart failure 8.4 9.4 10.5 6.9 10.4 12.5 12.0 10.9 12.3
History of stroke 11.2 11.1 13.1 11.1 12.5 12.4 17.7 15.1 15.1
Obstructive sleep apnea 11.9 11.6 10.9 11.3 11.0 10.9 10.9 10.2 10.3
Major depression episodes 9.7 9.2 10.5 10.5 10.8 11.9 12.4 11.7 13.2
Medical expenditures saving, $ per capitac 1,396 2,812 7,951 1,569 3,047 8,610 1,765 3,436 9,966
QALYs increase per person 0.05 0.10 0.21 0.06 0.11 0.23 0.07 0.12 0.26
Sick days reduction per person 0.5 0.7 1.8 0.5 0.8 1.7 0.5 0.9 2.1
Average 3-year program costs, $c 1,300
Average weight loss, % 5.0 5.3 6.0
Sample size, n 2,152 1,892 1,588
Abbreviation: QALYs, quality-adjusted life years.
a Participants completing ≥4 lessons.
b Participants completing ≥9 lessons.
c Dollar estimates are 2014 US dollars value using a 3% discount rate.
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Appendix.
This file is available for download as a Microsoft Word document at http://www.cdc.gov/pcd/issues/2016/docs/15_0357_Appendix.docx.
[DOC — 315 KB].
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